Abstract
BackgroundSclerostin is an osteocyte-secreted protein that negatively regulates osteoblasts. Wnt signaling may be crucial in the pathogenesis of impaired bone quality in type 2 diabetes mellitus (T2DM). The possibility that currently studied antisclerostin bone-forming agents could be useful to T2DM patients with osteoporosis needs further investigations.AimThe aim of this study was to investigate the relationship between serum sclerostin and bone mineral density in T2DM patients, in comparison with nondiabetic individuals.Patients and MethodsThis study was conducted on 21 T2DM patients and 22 nondiabetic individuals. All participants were 60 years or older. They underwent history taking, clinical examination, routine lab investigations, and glycated hemoglobin assessment. Serum sclerostin was measured by ELISA. Bone mineral density (BMD) was measured at the left femoral neck and lumbar spine.ResultsSerum sclerostin level was significantly higher in T2DM patients compared with nondiabetic individuals. Male participants showed significantly higher sclerostin levels among the nondiabetic individuals, whereas this difference was not significant among T2DM patients. The Bone mineral density (BMD) and f-values of T2DM patients and the nondiabetic group were not significantly different. We found a significant positive correlation between sclerostin level and lumbar spine BMD among nondiabetic individuals, whereas among T2DM patients, this correlation was not significant. Sclerostin levels did not show a significant difference between diabetic osteoporotic and diabetic nonosteoporotic patients.ConclusionPatients with T2DM have raised sclerostin levels that, unlike those in nondiabetic individuals. are not correlated with BMD. This pathological condition that is specific to diabetes necessitates further study, careful assessment of the role of antisclerostin therapy, and probable dose adjustment for osteoporosis in T2DM patients.
Highlights
Sclerostin is a glycoprotein secreted by osteocytes, which is a potent inhibitor of osteoblastogenesis [1]
Aim The aim of this study was to investigate the relationship between serum sclerostin and bone mineral density in type 2 diabetes mellitus (T2DM) patients, in comparison with nondiabetic individuals
Serum sclerostin level was significantly higher in T2DM patients compared with nondiabetic individuals
Summary
Sclerostin is a glycoprotein secreted by osteocytes, which is a potent inhibitor of osteoblastogenesis [1]. Sclerostin, after secretion by osteocytes, travels through osteocyte canaliculi to the bone surface at which it binds to coreceptors low-density lipoprotein receptorrelated protein (LRP5 and LRP6) and thereby reduces osteoblastogenesis and bone formation [2]. Humanized monoclonal antibodies to sclerostin cause enhanced Wnt signaling and an increase in bone mass in rodents and nonhuman primates [4]. Amgen/UCB reported in a press release (http://www.amgen.com) some of the results from the phase II study comparing the sclerostin antibody with placebo for the treatment of postmenopausal osteoporosis in ∼400 postmenopausal women with low bone mineral density (BMD). Aim The aim of this study was to investigate the relationship between serum sclerostin and bone mineral density in T2DM patients, in comparison with nondiabetic individuals. Bone mineral density (BMD) was measured at the left femoral neck and lumbar spine
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
